Public tenders for chemotherapy in Germany

Find all Medical tenders in the world.
Finding business opportunities has never been easier.

Results for medical. Make a new search!

Pharmaceutical products

Deutsche Rentenversicherung Nordbayern | Published October 25, 2016
Winner
Buchen-Apotheke, Porzelt OHG
cpvs
33600000

Providing the Marbachtalklinik in Bad Kissingen with drugs, cytostatics, chemotherapy, vaccines and medical supplies.

Pharmaceutical products

Deutsche Rentenversicherung Nordbayern | Published July 19, 2016  -  Deadline August 19, 2016
cpvs
33600000

Awarding pharmacies supply contracts for the supply of rehabilitation clinics with drugs, cytostatics, chemotherapy, vaccines and medical supplies.

Conclusion of a framework agreement over renting hookups chemo toilets (6000589869-BwDLZ Castle)

Bundeswehrverwaltung_neu | Published September 11, 2013  -  Deadline October 14, 2013
cpvs
24955000

Conclude a framework contract for the hire of toilets have connections chemo conclude a framework contract for the hire of chemotherapy toilets, free connection with and without sinks including waste disposal and water supply, the period from 01.12.2013 to 30.11.2016

Site equipment and scaffolding work (0899-14 B-E-21)

 | Published May 31, 2014
cpvs

Site equipment and scaffolding work: - site equipment with safety fence, traffic signs, chemotherapy toilet incl 8 mths provision - 1,650 m2 cleaner-standing scaffolding surface oriented, load class 3, including for use, - 450 m2 clothing as protection against weathering Plan thickness 0.75 mm, incl for use, - 782 m expansion area oriented stationary scaffolding with console facade scaffolding, b = 30cm, incl for use, - 1 pcs scaffold stair tower for scaffold, including for use,

Pharmaceutical products

Deutsche Rentenversicherung Knappschaft-Bahn-See (KBS) | Published January 18, 2017
Winner
Chiesi GmbH, Haemato Pharm GmbH
cpvs
33600000

It may further agreements are concluded.

indications

1) Adults and children with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph +) chronic leukemia (CML), is not considered for a bone marrow transplant as a first line of treatment into consideration.

2) adults and children with Ph + CML in chronic phase after Versa gene of interferon alpha therapy, in accelerated phase or blast crisis.

3) Adults and children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) in combination with chemotherapy.

4) adult patients with relapsed or refractory Ph + ALL as monotherapy.

Adults with myelodysplastic / myeloproliferative diseases (MSD / MPD) associated with gene rearrangement of the PDGF receptor (platelet-derived growth factor).

Point II.2.14.

Reference is made to the information under Section II.1.4) and VI.3) of this notice and on the information of the continuing published on 20/12/2016 at the above reference number.

Pharmaceutical products

GWQ ServicePlus AG | Published February 25, 2017  -  Deadline November 10, 2017
cpvs
33600000

Earliest Start treaty is the 01/04/2017.

This contract can at any time of the contract period all interested companies to join the same conditions (authorization model).

Until the start of exclusive contracts this transitional arrangement is open to all market participants to join.

Upon receipt of contracts / statement and evidence to 10/03/2017 signed an initial message can be realized to 01/04/2017.

The following documents must be provided:

- Signed contract in duplicate;

- Proof of the regulatory drug approval by extract from the public part of the AMIS database;

- Signed self-declaration (Appendix 3).

The Use Agreement applies to imatinib preparations, which are used for the following patent-free indications:

Adults and children -positive patients with newly diagnosed Philadelphia chromosome (bcr-abl) (Ph +) chronischermyeloischer leukemia (CML), is for a bone marrow transplant as a first line of treatment is not considered drawn.

Adults and children with Ph + CML in chronic phase after failure of interferon-alpha therapy, indians accelerated phase or blast crisis.

Adults and children with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) in combination with chemotherapy.

Adult patients with relapsed or refractory Ph + ALL as monotherapy.

Adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated mitGenumlagerungen of PDGFRezeptors (platelet-derived growth factor).

Adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRalpha- rearrangement.

To treat adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult mitrezidivierendem and / or metastatic DFSP who are not eligible for surgical treatment in question.

The discount agreement does not have any regulations imatinib preparations of the sort that are used due to the still under patent protection indication:

To treat c-Kit (CD 117) positive unresectable and / or metastatic malignant gastrointestinal stromal tumors (GIST) in adults;

Patients with a low or very low risk of recurrence should not receive adjuvant treatment.

A sample letter is available as an annex to the contract documents.

Guard services

Bau- und Liegenschaftsbegtrieb NRW | Published February 18, 2017  -  Deadline March 22, 2017
cpvs
79713000, 90000000, 45113000, 45315600

By restructuring restructure the Major General Baron von Gersdorff Barracks site is planned in Euskirchen. In this, however, no suitable infrastructure is currently available or could be adapted structurally and economically. This results in the need for new construction work on site described. In the entire project is 7 individual projects with a total volume of around € 100 000 000 EUR (incl. Incidental costs) in a realization period of about 3 years (execution), each with different planning participants and different security classifications. It is nonetheless of the construction of seven buildings and the reorganization of the supply and disposal as well as the outdoor facilities. The projects are to be realized almost simultaneously. Before setting up this great construction z. T. interim measures are necessary to make possible to the termination for the redevelopment of the building sites.

Parent site equipment

Central waste disposal

Baulogistik and surveillance - KG 700

Baustrom - low and medium voltage systems DIN 18382

Construction water and -abwasser

Approximately 900 days

Control and monitoring of people and vehicles to the site

Approximately 900 days access control, with preparation of construction site ID cards and security

Central Waste Management with container provision, waste management and documentation

38 St. standard containers as construction management building for the AG, incl. IT / PBX

Provision of 7 sanitary containers and 10 chemotherapy toilets for contractor

3300 m site fence, closed and barred, with additional climb guard

1 St. Bauschild and signage and safety measures

Temponäre Bausch Had conditioning

Winterbaubeheizung

6200 m 2 Construction areas (construction road, industrial)

Parent Baustromanlage, construction site lighting.

Pharmaceutical products

Deutsche Rentenversicherung Knappschaft-Bahn-See (KBS) | Published December 20, 2016  -  Deadline December 5, 2018
cpvs
33600000

18 Medicines Act are.

The conclusion of the contract or accession shall be effected by the required self-declarations and equipment and the contract or contracts signed are sent to the KBS

In any event, the agreements will terminate on 31.1.2019.

indications:

1) Adults and children with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph +) chronic leukemia (CML), is not considered for a bone marrow transplant as a first line of treatment into consideration.

2) adults and children with Ph + CML in chronic phase after failure of interferon-alpha therapy, in accelerated phase or blast crisis.

3) Adults and children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) in combination with chemotherapy.

4) adult patients with relapsed or refractory Ph + ALL as monotherapy.

5) adults with myelodysplastic / myeloproliferative diseases (MSD / MPD) associated with gene rearrangement of the PDGF receptor (platelet-derived growth factor).

6) Adults with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement.

7) adults with unresectable dermatofibrosarcoma protuberans (DFSP) and adults with recurrent and / or metastatic DFSP who are not eligible for surgical treatment in question.

The conclusion of the contract or accession shall be effected by the required self-declarations and equipment and the contract or contracts signed are sent to the KBS

In any event, the agreements will terminate on 31.1.2019.

Pharmaceutical products

DAK-Gesundheit | Published December 24, 2016  -  Deadline December 5, 2018
cpvs
33600000

It ends automatically regardless of the entry into force of the exclusive contract.

Conditions for the conclusion, or the eventual access to the first coming into force on 02.01.2017 contracts is the complete and timely transfer of the following evidence / statements / equipment to that given below contact person at the DAK-G:

letter of offer

III.1.1.).

III.1.1.).

III.1.1.).

III.1.1.).

Recognition of the contractual stipulations of the DAK health, esp. The given discounts by signing provided with a company stamp Treaty (3-fold in the original).

The completed Appendices 1 and 2 to the Contract (each with 3 compartments in the original).

III.1.2.).

The documents must be submitted by post at:

DAK health

Affinass

Nagelsweg 27-31

20097 HH

Documents the DAK health available by the 5th of the previous month.

indications:

1) adult and pediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph +) chronic myeloid leukemia (CML) for whom bone marrow transplantation is not considered as a first line of treatment into consideration.

2) adult and pediatric patients with Ph + CML in chronic phase after failure of interferon-alpha therapy, in accelerated phase or blast crisis.

3) adults and children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) in combination with chemotherapy.

4) adult patients with relapsed or refractory Ph + ALL as monotherapy.

5) adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with rearrangements of the PDGF receptor (platelet-derived growth factor).

6) adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR? Rearrangement.

7) adults with recurrent and / or metastatic DFSP who do not come with unresectable dermatofibrosarcoma protuberans (DFSP) and adult for a surgical treatment in question.

Pharmaceutical products

GWQ ServicePlus AG | Published May 26, 2017
Winner
Medicopharm AG
cpvs
33600000

The earliest start of the contract is 1.4.2017.

The contract may be open to all interested parties on the same terms at any time during the term of the contract (admission model).

Until the start-up contracts, this transition agreement is open to all market participants for accession.

Upon receipt of the signed contracts / declaration and proof of 10 March 2017, a first-time announcement on 1 April 2017 can be realized.

The following documents must be submitted:

- signed contract in duplicate;

- proof of approval by means of an extract from the public part of the AMIS database;

- signed declaration (Annex 3).

The discount contract applies to imatinib preparations which are used for the following patent-free indications:

Adults and children with newly diagnosed Philadelphia-chromosome (bcr-abl) -positive (Ph +) chronic myelogenous leukemia (CML) for which bone marrow transplantation is not considered as an initial treatment option.

Adults and children with Ph + -CML in the chronic phase after failure of interferon alpha therapy, in the accelerated phase or in the bladder crisis.

Adults and children with newly diagnosed Philadelphia chromosome-positive acute lymphocytic leukemia (Ph + ALL) in combination with chemotherapy.

Adults with relapsed or refractory Ph + ALL as monotherapy.

Adults with myelodysplastic / myeloproliferative diseases (MDS / MPD) in association with gene transitions of the PDGF receptor (platelet-derived growth factor).

Adults with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR alpha- rearrangement.

For the treatment of adults with non-resectable Dermatofibrosarcoma protuberans (DFSP) and adults with recurrent and / or metastatic DFSP that are not eligible for surgical treatment.

The discount agreement does not deal with any prescriptions of imatinib preparations which are used on the basis of the still patent-protected indication:

For the treatment of c-kit (CD 117) positive non-resectable and / or metastatic malignant gastrointestinal stromal tumors (GIST) in adults;

Patients with low or very low recurrence risk should not receive adjuvant treatment.

A sample letter is available as an annex to the contract documents.

Pharmaceutical products

Vergabestelle der AOK Rheinland-Pfalz/Saarland – Die Gesundheitskasse | Published January 31, 2017  -  Deadline December 31, 2018
cpvs
33600000

8 SGB V to products containing the substance imatinib (ATC code: L01XE01) - unpatented indications - within the time period from 01.03.2017 until 02.28.2019 anytime possibility of contract (open-house model).

Precondition for participation in this contract is the approval of at least one of the following patent-free indications:

a) adults and children -positive patients with newly diagnosed Philadelphia chromosome (bcr-abl) (Ph +) chronic myeloid leukemia (CML), is not considered for a bone marrow transplant as a first line of treatment into consideration.

b) adults and children with Ph + CML in chronic phase after failure of interferon-alpha therapy, in accelerated phase or blast crisis.

c) Adults and children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) in combination with chemotherapy.

d) adult patients with relapsed or refractory Ph + ALL as monotherapy.

e) adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with rearrangements of the PDGF receptor (platelet-derived growth factor).

f) adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα- rearrangement.

g) To treat adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgical treatment in question.

This discount agreement for imatinib preparations not comprising the patented indications:

h) To treat c-Kit (CD 117) positive unresectable and / or meta-stasierter malignant gastrointestinal stromal tumors (GIST) in adults

Patients with a low or very low risk of recurrence should not receive adjuvant treatment.

1 with the following or similar content:

a) The drug imatinib has a patented and non-patented application.

1 a) - g) listed unpatented indications.

c) If you treat an insured person who suffers from one of these patent-free indications, please prescribe imatinib as an active ingredient.

1 h) - i) above patented indications.

e) If you treat an insured person who suffers from one of these patented indications, please prescribe Glivec.

Since lack of input options (lack of space) the description of the procurement under this point can not be fully listed, the continuation of the carried out "description of the procurement" under "VI.3) Additional information".

Supply of medicines to hospitals Ostallgaeu-Kaufbeuren including pharmaceutical and pharmaco advice.

Kliniken Ostallgäu-Kaufbeuren A.d.ö.R. | Published November 27, 2013  -  Deadline January 21, 2014
cpvs
33600000, 85149000

The clinics Ostallgaeu purchase Beuren, Adö.R., is I to a hospital network in community sponsorship with locations in Kaufbeuren, Buchloe and feet. The hospital Kaufbeuren has as a focal supplier (supply level 2) over 360 approved beds. The clinic feet (100 regular beds + 25 beds geriatric rehabilitation department) and the clinic Buchloe (120 planned beds) are hospitals for basic and standard care the level of care 1 Support the clinics Ostallgaeu-Kaufbeuren are the county and the city Ostallgaeu Kaufbeuren. The clinics Ostallgaeu-Kaufbeuren have a total of 580 planned beds with the following departments and clinical areas: - General, Visceral, Thoracic and Vascular Surgery - Trauma Surgery, Orthopaedic Surgery, - Cardiology / Electrophysiology, - Gastroenterology / Diabetology / Endocrinology, - Oncology / Hematology - OB / GYN - ENT, - eyes - Urology - Pediatrics - Vein Surgery, Lymphology, wound treatment - Anaesthesia / Intensive Care - Radiology - palliative care. The latches are equipped with modern technology and medicine combine high quality medicine with comfortable accommodation and good service. Is put out to tender to supply the clinics Ostallgaeu-Kaufbeuren for all medicines, including chemotherapy drugs, as well as a comprehensive pharmaco-economic advice. The annual turnover of the clinics with medicines currently stands at around EUR 1.9 million. Collection of the drug can be done by the clinics themselves, alternatively the delivery to each site by the pharmacy is possible. The beginning of the supply should be to 07.01.2014. With the supplying pharmacy is foreseen to conclude a supply contract according to § 14 of the ApoG with a term of 4 years and the option of a yearly renewal. When the supply of medicines are the relevant laws, regulations, professional regulations and regulatory decrees, especially those on the marketing of medicinal products and on the operation of pharmacies to comply. The supply arrangement must be approved by the Government of Swabia to § 14 para 5 ApoG. As a mandatory condition for the approval of the supply contract has a maximum delivery time for acute cases of max. Be ensured 1.5 hours. The focus is on the one hand to low medication prices, and inexpensive as possible supply fee for the appointment of a suitable pharmacy to supply the clinics Ostallgaeu-Kaufbeuren. Secondly, a pharmacy is sought, the continuing to make a pharmacoeconomic consulting with the objective of reducing drug consumption, optimizing the prescribing behavior of physicians and a switch to each cheapest substitution preparations. To achieve this goal, an intensive on-site use by employees of the pharmacy in the hospital and intensive collaboration with the hospital staff must be guaranteed. It is expected from the pharmacy that they can make infusions, sterile dosage forms (also on a larger scale), non-sterile formulations and chemotherapeutics or prepare and also prove this.
  • 1